Two Consecutive Invasive Surgeries Utilizing Zymogen Protein C (ZPC) That Enhanced Patient Safety and Reduced Costs.

Area of Science:

• Hematology
• Surgical Procedures

Background:

• Protein C deficiency leads to hypercoagulability and increased risk of deep vein thrombosis (DVT) and pulmonary emboli (PE).
• Managing hypercoagulable patients undergoing major surgery requires careful consideration of anticoagulant and procoagulant therapies.

Observation:

• An 84-year-old male with protein C deficiency and a history of DVT/PE underwent simultaneous hip replacement and spinal stenosis correction.
• The patient received perioperative zymogen protein C (ZPC) without other anticoagulants, achieving successful surgical outcomes.
• No instances of clotting or excessive bleeding were observed during or after the procedures.

Findings:

• Perioperative administration of zymogen protein C effectively managed hypercoagulability in a complex surgical case.
• This approach facilitated two major surgeries in a single procedure, potentially reducing overall treatment costs and ZPC usage.
• The patient experienced an uneventful recovery without thrombotic or hemorrhagic complications.

Implications:

• Zymogen protein C administration is emerging as a viable strategy for managing hypercoagulable patients during high-risk invasive surgeries.
• This case highlights the potential for ZPC to enable safer, more cost-effective surgical interventions.
• The therapeutic approach may extend to acquired protein C deficiency and other conditions involving clotting and inflammation, such as sepsis and pregnancy.